Opus Genetics IRD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's EPS (diluted)?
- Opus Genetics (IRD) reported EPS (diluted) of -$0.75 in Q1 2026.
- How has Opus Genetics's EPS (diluted) changed year-over-year?
- Opus Genetics's EPS (diluted) decreased by 212.5% year-over-year, from -$0.24 to -$0.75.
- What is the long-term trend for Opus Genetics's EPS (diluted)?
- Over 4 years (2021 to 2025), Opus Genetics's EPS (diluted) has grown at a -34.7% compound annual growth rate (CAGR), from -$4.52 to -$0.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.